EGFR 19Del and 21L858R mutations are associated with distinct expression patterns of VEGFR1 and CD34, which may underlie differential responses to anti-angiogenic therapy and inform future combination treatment strategies.

2 days ago

Journal

EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

PALOMA-2: A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=520, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Aug 2028

3 days ago

Trial completion date

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation

Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)

ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy (clinicaltrials.gov)

P2, N=84, Not yet recruiting, Hebei Medical University Fourth Hospital

3 days ago

New P2 trial • Circulating tumor DNA

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

Semena (befotertinib)

Feasibility of EGFR Mutation Testing Without Nucleic Acid Extraction in Scraped Cytologic Samples Using the Idylla Platform. (PubMed, Diagn Cytopathol)

These findings indicate that EGFR mutation testing can be accurately performed on scraped cytologic material using the Idylla platform without prior nucleic acid extraction, with caution advised for specimens with low absolute tumor cellularity. The proposed workflow is technically feasible in any pathology laboratory, potentially enabling shorter turnaround times, and broader access to EGFR testing in routine clinical practice.

3 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR exon 19 deletion

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=64, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting

4 days ago

Enrollment open

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive

Tagrisso (osimertinib)

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC (clinicaltrials.gov)

P2, N=46, Not yet recruiting, Massachusetts General Hospital

4 days ago

New P2 trial • IO biomarker

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • ROS1 fusion

carboplatin • pemetrexed • Yidafan (ivonescimab)

Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review. (PubMed, Front Oncol)

The patient received first-line osimertinib combined with pemetrexed/cisplatin, achieving durable disease control for 17 months...Treatment was switched to alectinib, leading to significant tumor regression and partial response. This case illustrates that in triple-positive NSCLC, initial EGFR-TKI combined with chemotherapy can achieve long-term control, while dynamic molecular profiling at progression is essential for identifying resistance mechanisms. Sequential targeted therapy guided by NGS remains a cornerstone for precision management in this complex molecular subtype.

4 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B)

PD-L1 expression • EGFR mutation • PD-L1 overexpression • HER-2 amplification • EGFR exon 19 deletion • ALK positive • ALK rearrangement • ALK fusion

cisplatin • Tagrisso (osimertinib) • Alecensa (alectinib) • pemetrexed • simmitinib (SYHA1817)

Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations. (PubMed, Front Oncol)

Of these, two patients were treated with a third-generation TKI: 1 achieved SD and the other achieved partial response (PR). This integrated retrospective analysis suggests that third-generation EGFR-TKIs may provide disease control (PR/SD) and prolonged PFS in a subset of NSCLC patients harboring uncommon EGFR p.L747P or p.L747S mutations, particularly those with co-existing sensitizing mutations or central nervous system metastases (CNS).

4 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

SAVANNAH: Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (clinicaltrials.gov)

P2, N=367, Active, not recruiting, AstraZeneca | Trial completion date: May 2025 --> Dec 2026

6 days ago

Trial completion date

MET (MET proto-oncogene, receptor tyrosine kinase)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET overexpression

Tagrisso (osimertinib) • Orpathys (savolitinib)

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (clinicaltrials.gov)

P2, N=80, Recruiting, Stanford University | Trial primary completion date: Dec 2025 --> Dec 2026

6 days ago

Trial primary completion date • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement • ROS1 rearrangement • EGFR positive

cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel

Korea Post Marketing Surveillance (PMS) Study of Vizimpro (clinicaltrials.gov)

P=N/A, N=188, Completed, Pfizer | Recruiting --> Completed

6 days ago

Trial completion

EGFR (Epidermal growth factor receptor)

EGFR L858R • EGFR exon 19 deletion

Vizimpro (dacomitinib)

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study (clinicaltrials.gov)

P=N/A, N=30, Recruiting, Second Affiliated Hospital of Nanchang University

6 days ago

New trial

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

Avastin (bevacizumab)